GOLDSMITH MARK A 4

What Happened

• Mark A. Goldsmith, President & Chief Executive Officer of Revolution Medicines (RVMD), exercised 120,000 option shares and sold 120,000 common shares in an open-market transaction on April 15, 2026.
• He exercised 23,244 options at $4.09 (acquiring shares for $95,068) and 96,756 options at $4.73 (acquiring shares for $457,656), then sold 120,000 shares at a weighted-average price of $150.09 for total proceeds of $18,010,488. The exercise cost totaled $552,724, so the sale minus exercise cost was about $17.46M.
• The option exercises are coded M (exercise of derivative) and the sale is coded S (open-market sale). This appears to be a same-day exercise-and-sell (cashless-style outcome) rather than a buy-and-hold purchase.

Key Details

• Transaction date: 2026-04-15; Form 4 filed: 2026-04-17 (timely filing).
• Option exercises: 23,244 @ $4.09 ($95,068) and 96,756 @ $4.73 ($457,656).
• Open-market sale: 120,000 shares @ weighted avg $150.09 = $18,010,488 (executed in multiple trades at $150.00–$150.64).
• Shares owned after transaction: total beneficial ownership not shown in this excerpt; filing notes include 201,150 restricted stock units.
• Notable footnotes: transaction executed under a 10b5-1 trading plan adopted Dec 19, 2024 (F1); multiple family trusts hold additional shares (F4–F6).
• No indication this Form 4 was late.

Context

• For retail investors: this was an insider exercising options (converting derivatives into shares) and selling those shares the same day. Such transactions often reflect pre-established trading plans (here, a 10b5-1 plan), so they should not be read as a direct signal of management’s near-term view.
• The filing shows both the low exercise prices and the high sale price, illustrating the substantial paper gain realized by exercising and immediately selling.